Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada
Martins D, Khuu W, Tadrous M, Juurlink DN, Mamdani MM, Paterson JM, Gomes T. Pharmacoepidemiol Drug Saf. 2019; 28(5):726-33. Epub 2019 Mar 14.